Persistence of hepatitis B surface antibody and immune memory to hepatitis B vaccine among medical college students in Madinah

Waleed Mahallawi

From the Department of Clinical Laboratory Sciences, Taibah University, Madinah, Saudi Arabia and Department of Clinical Infection, Microbiology and Immunology, University of Liverpool, United Kingdom

Correspondence: Dr. Waleed Mahallawi ∙ Clinical Laboratory Sciences, Taibah University, Prince Naif St. Madinah 42362, Saudi Arabia ∙ T: +966-14-8618888 ext: 3666 ∙ wmahallawi@gmail.com ∙ ORCID: http://orcid.org/0000-0001-6977-9006

Citation: Mahallawi W. Persistence of hepatitis B surface antibody and immune memory to hepatitis B vaccine among medical college students in Madinah. Ann Saudi Med 2018; 38(6): 413-419. DOI: 10.5144/0256-4947.2018.413

Received: July 16, 2018
Accepted: November 26, 2018
Published: December 6, 2018
Copyright: Copyright © 2018, Annals of Saudi Medicine, Saudi Arabia. This is an open access article under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). The details of which can be accessed at http://creativecommons.org/licenses/by-nc-nd/4.0/
Funding: None.

BACKGROUND: Globally, about 300 million people are infected with hepatitis B virus (HBV). Among the effective approaches to fight HBV infection is immunization. In 1989, an obligatory hepatitis B vaccine program was launched in Saudi Arabia.

OBJECTIVE: Assess hepatitis B surface antibody (anti-HBs) levels among the medical students before and after receiving booster doses of HBV vaccine.

DESIGN: Cross-sectional.

SETTING: Taibah University.

SUBJECTS AND METHODS: Students born between 1993 and 1995 were recruited in this study from the Occupational Health Clinic. Students were screened for anti-HBs levels using chemiluminescent microparticle immunoassay (CMIA) before and after booster HBV vaccine doses.

MAIN OUTCOME MEASURES: Anti-HBs levels before and after booster doses.

SAMPLE SIZE: 335.

RESULTS: About half of participants (n=164, 49%) had protective anti-HBs levels (≥10 mIU/mL) to the original primary series of HBV vaccine and received no booster doses. The remaining 171 (51%) participants were at risk of HBV infection since their anti-HBs levels were <10 mIU/mL, despite having received the original primary HBV vaccine. The levels of anti-HBs were higher in female than in male students (P<.001). In addition, female students showed a stronger humoral immune response to the booster vaccine than male students (P<.001). When participants were given the three boosters, most participants (98.3%) showed anti-HBs levels of ≥10 mIU/mL. The results also showed a strong correlation between pre-booster and post-booster anti-HBs levels in the ≥10 mIU/mL group (r²=0.52, P<.001) but not in <10 mIU/mL group (r²= 0.003, P=.53).

CONCLUSION: A considerable portion of the participants (about 51%) were at risk of HBV infection since their anti-HBs levels were <10 mIU/mL. Booster doses significantly trigger memory immune response and this ensured their protection against the virus. Pre-booster anti-HBs level are a good predictive of post-booster anti-HBs levels in ≥10 mIU/mL group.

LIMITATIONS: The sample size was small. Shortage of collaborators.

CONFLICT OF INTEREST: None.
HBV is a small DNA virus that belongs to the Hepadnaviridae family. The replication cycle of HBV involves an RNA intermediate that can incorporate into the host genome and subsequently persist in infected cells. Accurate diagnosis of HBV infection is based on a group of clinical, biochemical, histological, and serologic results. Several viral antigens and their corresponding antibodies can be detected in blood after infection with HBV. For example, a positive hepatitis B surface antigen means an active (acute or chronic) HBV infection. The presence of hepatitis B e-antigen (HBeAg) indicates a high-level of HBV replication and infectivity. The positivity of this marker indicates an immune response to HBV infection and immune response to vaccination. In the latter case, the titer can be measured to evaluate vaccine effectiveness.

HBV is considered a global health problem that accounts for about one million deaths annually as it is linked to the development of liver cirrhosis and hepatocellular carcinoma. A substantial decrease in the number of infections caused by HBV is attributed to HBV vaccination programs for infants, children, adolescents and at high-risk populations, and to the advances in the screening of blood products and safe injection techniques.

Saudi Arabia has witnessed a significant decrease in the last two decades in the prevalence of HBV due to the implementation of the childhood vaccination program against the virus, which was launched in 1989. One year later, a catch-up vaccination program supplemented for children at school entry, healthcare workers, and other high-risk groups was implemented. Therefore, almost all Saudis aged 24 years or younger had been vaccinated either at birth, or at school entry.

The effectiveness of vaccination programs in inducing anti-HBs has been evaluated in many countries. In a significant portion of the populations, anti-HBs levels were not high enough to guarantee protection against HBV. Therefore, in the current study, anti-HBs levels in the plasma of medical college students in Almadinah city, Saudi Arabia were evaluated. In addition, levels of anti-HBs were measured after the students had received booster doses.

**SUBJECTS AND METHODS**

**Subjects**

Students from medical colleges at Taibah University were invited to participate in this study at the Occupational Health Clinic at Medical Center at the Taibah University in Almadinah city. All subjects were born between 1993 and 1995 and had completed the original primary series of HBV vaccine. Students were initially screened for plasma levels of anti-HBs as a requirement before starting the obligatory one-year internship. The students were then invited to receive the booster vaccine for HBV. Students who agreed to complete the study were asked to present certificates for having received booster dose/doses. The students who did not provide the certificate were excluded from the post-booster analysis. The students were given three boosters (0, 1 and 3 months, dose 10 μg recombinant vaccine) and plasma samples were obtained 4 weeks after each booster. Informed consent was obtained from all students after full explanation of the study objectives and procedures. In addition, the study was approved by the ethics committee of Taibah University. The study was conducted between 2015 and 2017.

**Chemiluminescence assay**

About 5 mL of venous blood was obtained from each participant in EDTA tubes. Samples were centrifuged at 3000 xg for plasma separation. Plasma samples were stored at –20° C until used. The ARCHITECT HBsAg assay was used in the current study for the quantitative determination of hepatitis anti-HBs in human plasma samples. The assay is based on chemiluminescent microparticle immunoassay technology. The assay kit was obtained from Abbott (Wiesbaden, Germany). The overall specificity of the assay was estimated to be 99.67%. The overall sensitivity was estimated to be 97.54%. The assay was performed using the ARCHITECT i1000SR System (Abbott Park, IL, USA). If the concentration of the specimen was greater than or equal to 10 mIU/mL, the specimen was considered reactive for anti-HBs; if it is less than 10 mIU/mL it was considered non-reactive. All tests were performed at Ministry of Health Regional Lab, King Fahad Hospital, Almadinah, Saudi Arabia.

**Statistical analysis**

All the calculations and statistical analysis were performed using GraphPad Prism statistical software (version 5, USA). Data were expressed as mean and standard deviation (SD). Two-group comparisons were performed using the Mann-Whitney test. Analysis that involved three groups or more was performed using ANOVA followed by the Tukey post hoc test.
The correlation between pre- and post-booster antibody levels was determined by the Spearman’s rank correlation test. A \( P < .05 \) was considered significant for all tests.

**RESULTS**

Enrollment totaled 335 students (Table 1). The mean (SD) age in years was 22.8 (0.9). About 26% of the sample were males. In addition, all participants were Saudi, from the Almadinah area and received the primary HBV vaccine during infancy. Finally, the time since vaccination was 21.3 (0.97) years. The final number of students who completed the whole study was 295 (88% of the total). To verify the effectiveness of HBV vaccine to induce a humoral immune response, all students were tested for the detection of anti-HBs in plasma. About 51% of the sample had anti-HBs plasma levels of < 10 mIU/mL (Table 2). In addition, a significant difference in the distribution of participants according to anti-HBs levels (<10 mIU/mL versus ≥10 mIU/mL) was observed between male and female students (Figure 1, \( P < .001 \)). When participants were given the three boosters, most participants (98.3%) showed anti-HBs levels of ≥10 mIU/mL. However, levels of anti-HBs were higher in female than male students (\( P < .001 \)), indicating a stronger humoral immune response to the booster vaccine in females.

About 97.3% of the participants had anti-HBs levels of ≥10 mIU/mL after the first booster (Table 3), indicating that almost all of the participants acquired immunity against HBV directly after the first booster. Significant differences (\( P < .01 \)) in the mean levels of anti-HBs suggested a stronger response after each booster (Figure 2). Finally, the correlation between pre-booster and post-booster anti-HBs levels in the <10 mIU/mL and ≥10 mIU/mL groups showed a strong correlation between pre-booster and post-booster anti-HBs levels in ≥10 mIU/mL group (\( r^2 = 0.52, P < .001 \), Figure 3B) but not in <10 mIU/mL group (\( r^2=0.003, P=.53 \), Figure 3A). Thus, pre-booster anti-HBs seems to be predictive of post-booster anti-HBs levels in the ≥10 mIU/mL group.

**DISCUSSION**

In the current study, anti-HBs levels among the medical

---

Table 1. Demographics of participants.

| Parameter                              | Value |
|----------------------------------------|-------|
| Age (mean and standard deviation), years | 22.82 (0.85) |
| Gender                                  |       |
| Male                                    | 90 (26.1) |
| Female                                  | 245 (73.1) |
| Ethnicity (n, %)                        |       |
| Saudi                                   | 335 (100) |
| Others                                  | 0 (0) |
| Residency (n, %)                        |       |
| Al Madinah area                         | 335 (100) |
| Others                                  | 0 (0) |
| Age at HBV vaccination                  |       |
| In infancy (0-3 years)                  | 335 (100) |
| Other ages                              | 0 (0) |
| Time since vaccinations (mean and standard deviation), years | 21.3 (0.97) |

Table 2. Frequency of protective levels of anti-HBs and levels of anti-HBs before and after receiving the third booster.

|                        | Pre-booster | Post-booster |
|------------------------|-------------|--------------|
|                        | <10 mIU/mL | ≥10 mIU/mL  | <10 mIU/mL | ≥10 mIU/mL |
| **Anti-HBs status**    |             |              |            |            |
| Total                  | 171 (51.0) | 164 (49.0)  | 5 (1.7)    | 290 (98.3) |
| Males                  | 62 (68.9)* | 28 (31.1)   | 2 (2.5)    | 79 (97.5)  |
| Females                | 109 (44.5) | 136 (55.5)  | 3 (1.4)    | 211 (98.6) |
| **Anti-HBs concentration (mIU/mL)** | |              |            |            |
| Total                  | 6.39 (2.0) | 236.4 (222) | 4.2 (2.3)  | 427.4 (314) |
| Males                  | 6.24 (1.9) | 244.5 (208) | 3.0 (1.4)  | 260.5 (243)* |
| Females                | 6.47 (2.1) | 234.7 (225) | 5.0 (1.5)  | 490.6 (315) |

Values are n (%) or mean (SD) mIU/mL. *Significant difference from females, \( P < .05 \). †Significant difference from females, \( P < .001 \).
students at Almadinah city, Saudi Arabia were examined. The results showed that about half of the students (51%) had a low protection level of anti-HBs (<10 mIU/mL), despite receiving the original primary HBV vaccine series. In addition, a spectrum of humoral immune response to HBV vaccine was also observed. A previous study from Egypt showed that about 40% of school children who received primary HBV vaccine series were not protected.23 Similar percentages were reported in previous studies from countries such as Taiwan,19,24 Europe,25-27 and the United States.18,28 However, 25% of medical students were not responsive in studies conducted in Italy.20,21 The high percentage of students with anti-HBs <10 mIU/mL could be because they responded to the vaccine, but the levels of the anti-HBs declined with time.29 This result is consistent with studies that showed decreased antibody level with increasing age.23,29,30 In addition, our results are consistent with several studies that concluded that continuing protection against HBV infection depends on immunological memory, which seems to last 10-15 years in immunocompetent individuals who respond adequately to the primary vaccination.31-33 Therefore, the scientific community and health authorities in Saudi Arabia should be urged to collaborate to do a larger long-term study similar to that by Bruce et al, 2016, which followed subjects for a period of thirty years.34 This is important to assess the suitability of the current vaccine for the Saudi population.

About 98% of the students had an anamnestic response after they have received three boosters of the vaccine. Thus, 2% of the population seems to not respond to the current vaccine and may be at risk of developing HBV. Similar post-booster outcomes have been reported in other populations.19,23,26 There was also a strong correlation between pre-booster anti-HBs level and post-booster anti-HBs status in the group with pre-booster anti-HBs levels of ≥10mIU/mL, but not in the non-responder group (<10mIU/mL). This indicates that pre-booster anti-HBs level can be used as a predictive factor for positive post-booster anti-HBs status.

Table 3. Frequency of protective levels of anti-HBs and levels of anti-HBs before and after the first, second and third booster

|                        | Pre-booster (n=335) | First dose (n=295) | Second dose (n=295) | Third dose (n=295) |
|------------------------|---------------------|--------------------|---------------------|-------------------|
| <10 mIU/mL             | 171 (51.0)          | 8 (2.7)            | 5 (1.7)             | 5 (1.7)           |
| >10 mIU/mL             | 164 (49.0)          | 217 (97.3)*        | 290 (98.3)          | 290 (98.3)        |
| Anti-HBs concentration (mIU/mL) | 119 (193)*         | 138.9 (127.8)      | 289.4 (211.8)       | 516.2 (337.2)     |

Values are n (%) or mean (SD). *Indicates significant difference from prebooster group, P<.001; † Indicates significant difference between all groups, P<.01.
This finding is consistent with studies conducted in Taiwan, Egypt, and the United States.

Females responded more strongly than male students, which is consistent with other studies that showed the same trend in terms of lower anti-HBs antibody titers in males compared with females. Gender differences in the response to HBV vaccine were reported by some previous studies. Similar findings were also reported in animal models. Thus, in addition to pre-booster anti-HBs, female gender is another predictive factor for post-booster anti-HBs status. It has been postulated that gender differences might be due to the opposite effects of sex hormone androgen and estrogen.

The inevitability of booster vaccination for HBV has been a subject of considerable argument as a decline in serum anti-HBs level essentially indicates a reduced protection and the need for a booster dose of the vaccine. According to WHO recommendations, booster immunization for HBV is not recommended and the protection lasts at least 20 years, possibly lifelong. However, several studies, including the present one, highlight the importance of booster doses to trigger the memory immune system and maintain a higher protective level of anti-HBs. Boosters will elicit an immune memory and offer reassurance of protective immunity against breakthrough infection. For immunocompromised patients, consistent testing for anti-HBs and a booster injection when the titer decreases below 10 mIU/mL are recommended.

In conclusion, a considerable portion of medical students (about 51%) were at high risk of HBV infection as their anti-HBs levels were <10 mIU/mL. Booster doses significantly triggered memory immune response, which ensured protection against the virus. Finally, pre-booster anti-HBs seems to be predictive of post-booster anti-HBs levels in subjects with ≥10 mIU/mL anti-HBs.
original article

REFERENCES

1. Ginzberg D, Wong RJ, Gish R. Global HBV burden: estimates and facts. Hepatol Int 2018;12:315-29. doi:10.1007/s12072-018-9864-8.

2. Lebalela TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49(5 Suppl):S13-21.

3. Xie M, Yang Z, Liu Y, Zheng M. The role of HBV-induced apoptosis in HBV replication and HBV related-HCC. Life sciences. 2018;205:107-12.

4. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology. 2003;38(5):1075-86.

5. Allain JP, Opare-Sem O. Screening and diagnosis of HBV in low-income and middle-income countries. Nature reviews. Gastroenterology & hepatology. 2016;13(11):643-53.

6. Leung N. Viral resistance in HBV infection: diagnosis, implications and management. Tropical gastroenterology: official journal of the Oriental Digestive Diseases Foundation. 2008;29(3):123-8.

7. Puccio C. How to manage HBsAg-negative chronic HBV infection with normal alanine aminotransferase levels in clinical practice? European journal of internal medicine. 2013;24(2):100-3.

8. Kuhns MC, Busch MP. New strategies for blood donor screening for hepatitis B virus nucleic acid testing versus immunoglobulin methods. Mol Diagn Ther. 2006;10(2):77-91.

9. Pawlotsky JM, Musheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, et al. Virologic monitoring of viral hepatitis in Saudi Arabia: implications for chronic hepatitis B. Liver international: official journal of the International Association for the Study of the Liver. 2016;36(6):775-82.

10. Lavanche D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of viral hepatitis. 2004;11(2):97-107.

11. Thio CL, Guo N, Xie C, Nelson KE, Ehhardt S. Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy. Lancet Infect Dis. 2015;15(8):981-5.

12. Alshayea AI, Eid GE, El-Hazmi MM, Alheetheel AF. Prevalence and characterization of occult hepatitis B infection among blood donors for chronic hepatitis B. Liver international: official journal of the International Association for the Study of the Liver. 2016;37(10):1114-9.

13. Abdo AA, Sanai FM, Al-Faleh FZ. Epidemiology of viral hepatitis in Saudi Arabia: are we off the hook? Saudi J Gastroenterol. 2012;18(6):349-57.

14. Menish ZA, Knawy BA, El-Saed A. Incidence trends of viral hepatitis A, B, and C seropositivity over eight years of surveillance in Saudi Arabia. Int J Infect Dis. 2010;14(2):115-20.

15. Alabd AA, Sanai FM. Viral hepatitis in Saudi Arabia. An unfinished story. Saudi Med J. 2015;36(7):785-6.

16. Al-Faleh FZ, Ayasha EA, Arif M, Ramia SI, Al-Rashed AL, Al-Jeffry M, et al. Seroprevalence of hepatitis B virus infection in Saudi Arabian children: a baseline survey for mass vaccination against hepatitis B. Journal of infection. 1992 Mar 1;24(2):197-206.

17. Bialek SR, Bower WA, Novak R, Helgenberger L, Auerbach SB, Williams JT, et al. Persistence of post-infection protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. The Pediatric infectious disease journal. 2008 Oct 1;27(10):881-5.

18. Chen YS, Chu CH, Wang JH, Lin JS, Chang YC. Predictors of Booster Response to Hepatitis B Vaccine at 15 years of age: A Cross-Sectional School-Based Study. Peditricts and neonatolgy. 2011;57(4):302-9.

19. Dini G, Toletone A, Barabersi I, Debarbieri N, Massea E, Pagnanico C, et al. Persistence of protective anti-HBs antibodies levels and anamnestic response to HBV booster vaccination: a cross-sectional study among healthcare students 20 years following the universal immunization campaign in Italy. Human vaccines & immunotherapeutics. 2017 Feb 1;13(2):440-4.

20. Pileggi C, Papadopoli R, Bianco A, Pavia M. Hepatitis B vaccine and the need for a booster dose after primary vaccination. Vaccine. 2017;35(46):6302-9.

21. Su FH, Chu FY, Bai CH, Lin YS, Hsuie YM, Sung FC, Yeh C. Efficacy of hepatitis B vaccine boosters among neonatally vaccinated university freshmen in Taiwan. Journal of hepatitis. 2013 Apr 1;58(4):684-9.

22. Salama I, Sami S, Saleh M, Mohsen A, Elserougy S, Emam H, et al. Immunogenicity of compulsory and booster doses of hepatitis B vaccine among children in Cairo, Egypt. Journal of Egyptian Public Health Association. 2017 Jun 1;92(2):77-85.

23. Wu TW, Lin HW, Wang YC. Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology. 2013;57(11):37-45.

24. Anderson CL, Remschmidt C, Dobrindt FP, Falkenhorst G, Zimmermann R, Wichmann O, et al. Hepatitis B immune status in adolescents vaccinated during infancy: a retrospective cohort study from a pediatric practice in Germany. Human vaccines & immunotherapeutics. 2016 Mar 31;12(3):779-84.

25. Brunskole Hummel I, Huber B, Wenzel LJ, Jilg W. Markers of Protection in Children and Adolescents Six to Fourteen Years After Primary Hepatitis B Vaccination in Real Life: A Pilot Study. The Pediatric infectious disease journal. 2016;35(3):286-91.

26. Zanetti AR, Mariano A, Romanò L, D’Amelio R, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, Negroni FS, Parlatò A. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. The Lancet. 2005 Oct 15;366(9494):1379-84.

27. Keck JW, Bulkow LR, Racznicki GA, Negus SE, Zanis CL, Bruce MG, et al. Immune response to hepatitis B vaccine with high antigen content in children where endemicity is low. J Infect Dis. 2008;29;25(39-40):6958-64.

28. Boxall EH, J AS, El-Shukrini K, Kelly DA. Long-term persistence of immunization to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis. 2004;190(7):1264-9.

29. Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology. 1999;29(3):954-9.

30. Bruce MG, Bruden D, Hurlbut D, Zanis C, Thompson G, Rea L, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and a response to a booster dose. The Journal of infectious diseases. 2016 Jan;214(1):16-22.

31. Lu IC, Jean MC, Lin CW, Chen WH, Peng DS, Lin CW, et al. Predictive factors for anti-HBs status after 1 booster dose of hepatitis B vaccine. Medicine. 2016 Sep;95(39).

32.Yang S, Tian G, Cui Y, Ding C, Deng M, Yu C, et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Scientific reports. 2016 Jun 21;6:27251.

33. Sangfelt P, Uhnoo I, Reichard O, Weiland O. A low-dose intradermal hepatitis B vaccine programme in health-care workers and students is highly effective and cost saving: a retrospective follow-up survey in the clinical setting. Scand J Gastroenterol. 2008;43(4);465-72.

34. Kanda N, Tamaki K. Estrogen enhances hepatitis B virus (HBV) precore (pre-C) gene expression and production by human PBMCs. J Allergy Clin Immunol. 1999;103(2 Pt 1):282-8.

35. Abu Dayeh BK, Chung RT. Broadly neutralizing antibodies to hepatitis B: a new hope for immunization? Gastroenterology. 2008;134(7):2184-6.

36. Rand Dum LA, Hulseth KH, Chun HM, Crum-Cianflone NF, Ganesan A, Wientrob AC et al. The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis. American journal of epidemiology. 2010 Nov 4;171(1):84-93.

37. Huang JY, Beasley RP, Stevens CE, Szmurlo W. Immunogenicity of HBV vaccine in healthy Chinese children. Vaccine. 1983;1(1):10-2.

38. Pan HK, Zeng Y, Song XF, Zhang YJ, Xu XM, Zhang S. The response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults. Vaccine. 2014 Feb 18;32(10):1300-7.

39. Zhu FC, Sun KX, Pan HK, Yang ZH, Lu Y, Liang ZL et al. The immunogenicity in healthy infants and efficacy to prevent
mother to child transmission of Hepatitis B virus of a 10 ?g recombinant yeast-derived Hepatitis B vaccine (Hep-KSC). Vaccine. 2016 May 23;34(24):2656-62.

44. Al Ghamdi SS, Fallatah HI, Fetyani DM, Al-Mughales JA, Gelaidan AT. Long-term efficacy of the hepatitis B vaccine in a high-risk group. J Med Virol. 2013;85(9):1518-22.

45. Chiarakul S, Eunumjitkul K, Vuttiopas S, Vorapimol AR, Kaewkungwal J, Poovorawan Y. Seroprevalence and risk factors of hepatitis B virus infection among health care workers at the Institute of Neurology. J Med Assoc Thai. 2007;90(8):1536-45.

46. Petersen KM, Bulkow LR, McMahon BJ, Zanis C, Getty M, Peters H, Parkinson AJ. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. The Pediatric infectious disease journal. 2004 Jul 1;23(7):650-5.

47. Horowitz MM, Ershler WB, McKinney WP, Battista R, Parkinson AJ. Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. Ann Intern Med. 1988;108(2):185-9.

48. Chaves SS, Fischer G, Groeger J, Patel PR, Thompson ND, Teshale EH, et al. Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. Vaccine. 2012 Feb 21;30(9):1644-9.